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Abstract
Background: Thromboelastometry is a whole blood assay performed to evaluate the viscoelastic properties during blood clot formation and
lysis. Rotation thromboelastography (ROTEMW, Pentapharm GmbH, Munich, Germany) has overcome some of the limitations of classic
thromboelastography. So far, no clinical validation on reproducibility (inter- and intra-assay variability) and sample stability over time has
been published. Methods: To evaluate the pre-analytic aspects, sample stability over time was assessed in 48 patients in eight age groups.
Citrated blood was stored at room temperature. Tests measured every 30 min from T 0 min up to T 120 min on two ROTEMW devices were INTEM
(ellagic acid activated intrinsic pathway), EXTEM (tissue factor-triggered extrinsic pathway) and FIBTEM (with platelet inhibitor (cytochalasin D)
evaluating the contribution of fibrinogen to clot formation). Precision by intra- and inter-assay variability was evaluated at two points of time in
10 volunteers. Finally, reference intervals and effect of age and sex were evaluated. Results: Blood was stable over 120 min and no significant
differences in ROTEMW results were found. Maximum clot firmness measurements had a coefficient of variation of<3% for EXTEM,<5% for INTEM
and<6% for FIBTEM. For clot formation time, the coefficient of variation was<4% for EXTEM and<3% for INTEM. Coefficient of variation for angle
alpha was <3% for EXTEM and <6% for INTEM. The coefficient of variation for clotting time was <15% for both EXTEM and INTEM. Small but
significant differences between ROTEMW devices were found for maximum clot firmness in FIBTEM and INTEM as well as clot formation time and
alpha angle in INTEM. Conclusions: ROTEMW yields stable results over 120 min with a minimal variability on the same ROTEMW device. However,
small but significant differences between ROTEMW devices were observed. Analysis should be performed on the same ROTEMW device if small
differences are of importance for treatment.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Rotation thromboelastometry (ROTEMW) (ROTEMW delta,
Pentapharm GmbH, Munich, Germany), a methodology based
on thromboelastography originally described by Hartert more
than 50 years ago [1], is frequently used today to rapidly
assess the visco-elastic properties of the developing clot in
cardiac and transplant surgery as well as following trauma
[2—5]. ROTEMW documents the interaction of platelets with
the coagulation factors from initial platelet—fibrin interac-
tion, through platelet aggregation, clot strengthening and
fibrin cross-linking to eventual clot lysis. Within 30 min, a
ROTEMW tracing provides information on clotting factor§ Financial support: The work carried out in this article was supported by
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doi:10.1016/j.ejcts.2009.07.038activity, platelet function and any clinically significant
fibrinolysis [6,7].
The goal of this study was to assess stability and
reproducibility over time of ROTEMW. The lack of such a
study was alreadymentioned by Dunning et al. [8] in 2008 and
by Samama and Ozier [9] in 2003. Possible changes due to age
and sex were also of interest. In thromboelastography (TEGW
Haemoscope Corporation, Skokie, IL, USA), stability of
results over time is only achieved following a 30-min waiting
time after blood draw and before analysis [10]. Immediate
sample analysis, however, is desirable in the setting of an
acute bleeding event. We thus assessed stability over time for
ROTEMW.
2. Material and methods
This clinical trial was performed after obtaining
authorisation by the local ethics committee (KantonaleSurgery. Published by Elsevier B.V. All rights reserved.
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ber StV 27-2007).
Sample size (n = 48) was chosen based on statistical
considerations and on reported general practice. Horn and
Pesce showed that a minimum of 39 patients is needed for
establishing a 95% reference interval by power analysis [11].
In addition, Friedberg et al. reported in 2007 [12], that 50% of
laboratories enrol 21—50 subjects when establishing refer-
ence intervals. As a possible age or gender effect was of
interest, three male and three female patients in each of the
following eight age categories were included: below 20
years; 20—30 years; 30—40 years; 40—50 years; 50—60 years;
60—70 years; 70—80 years; and above 80 years.
Inclusion criteria were scheduled for a non-emergent
operation and signed written informed consent. Exclusion
criteria were known malignancy or immunosupression,
known coagulation disorders, anticoagulation in any form,
current treatment with heparin (other than routine pre-
operative thromboembolic prophylaxis with 3000 IU low-
molecular-weight heparin administered subcutaneously the
evening prior to the operation), use of acetyl salicylic acid
within the past 5 days, use of non-steroidal anti-inflamma-
tory agents within the past 24 h, known renal diseases or
plasma concentration of creatinine more than 120 mM and
liver diseases or increased plasma concentration of aspartate
aminotransferase (>50 U l1) or alanine aminotransferase
(>50 U l1) as well as patients not capable of understanding
the German language.
The study’s main objectives were to validate ROTEMW by
investigating (1) pre-analytic aspects (sample stability), (2)
reproducibility and precision of ROTEMW (intra- and inter-
assay variability), and (3) reference intervals and effect of
age and sex.
Several predefined tests were assessed: INTEM (ellagic
acid activated intrinsic pathway), EXTEM (tissue factor
triggered extrinsic pathway) and FIBTEM (with platelet
inhibitor (cytochalasin D) evaluating the contribution of
fibrinogen to clot formation). These three assays are
performed in citrated samples and represent counterparts
of routine tests of plasmatic coagulation: fibrinogen,
prothrombin time and activated partial thromboplastin
time. The two main differences between thromboelasto-
metric tests and plasmatic coagulation tests are (i) the
former is performed on whole blood, the latter on plasma,
and (ii) the former measures processes involving thrombin
generation, clot formation and clot lysis, the latter
processes leading up and until the initial generation of
thrombin. By using inhibitors of platelet function, the
developers of the assay have derived a functional test of
fibrinogen, called FIBTEM. This can be correlated with
functional fibrinogen tests in plasma. By comparing EXTEM,
the thromboelastometric test that uses tissue factor
(comparable to the prothrombin time test) as an activator,
with FIBTEM, one can deduce relevant information regarding
platelet function and factor XIII function, as both of these
contribute to EXTEM measurement.
In EXTEM, the extrinsic pathway is activated by thrombo-
plastin from rabbit brain to assess clot formation and
fibrinolysis. In INTEM, the intrinsic pathway is activated by
a contact activator to assess the clot formation and fibrin
polymerisation. In FIBTEM, the extrinsic pathway is activatedby tissue factor in presence of a platelet inhibitor to assess
the functional fibrinogen level.
Ten volunteers were sufficient to investigate precision and
reproducibility according to power analysis with 95%
confidence interval (CI). To investigate precision and
reproducibility of ROTEMW analysis, for inter-assay (on one
single ROTEMW device), reproducibility testing was per-
formed in the volunteers, after having obtained written
informed consent, withdrawing three tubes (Vacutainer
Brand, Belliver Industrial Estate, Plymouth, UK, 4.5 ml, 9
NC 0.129 M, a total of 18 ml per volunteer) of citrated blood,
the first tube (Vacutainer Brand, Belliver Industrial Estate,
Plymouth, UK, 4.5 ml, 9 NC 0.129 M) drawn was discarded to
exclude coagulation activation due to vein puncture and
blood withdrawal. Inter-device variability was tested using
the same samples on a second ROTEMW device. Intra-assay
variability was tested by performing duplicatemeasurements
at the time of the first blood withdrawal on the same device
using different channels and calculating the coefficient of
variation. At a second point of time, that is, 1 week later,
another three tubes (Vacutainer Brand, Belliver Industrial
Estate, Plymouth, UK, 4.5 ml, 9 NC 0.129 M, a total of 18 ml
per volunteer) of citrated blood were again withdrawn from
the same 10 volunteers to assess the reproducibility of the
two ROTEMW devices at the second point of time (week 2) as
compared with the first week. The 10 volunteers were nurses
or physicians from the Institute of Anaesthesiology, of the
University Hospital of Zurich, and the tests ran for 30 min.
After obtaining written informed consent from the
patients, eight tubes (Vacutainer Brand, Belliver Industrial
Estate, Plymouth, UK, 4.5 ml, 9 NC 0.129 M) of citrated blood
were withdrawn, a total of 36 ml of blood per patient. The
first tube (Vacutainer Brand, Belliver Industrial Estate,
Plymouth, UK, 4.5 ml, 9 NC 0.129 M) drawn was discarded
to exclude coagulation activation due to vein puncture and
blood withdrawal. In the 48 patients, INTEM, EXTEM and
FIBTEM were performed at T 1 = 0 min, T 2 = 30 min, T
3 = 60 min, T 4 = 90 min and T 5 = 120 min. The blood was
stored at room temperature. Tests were performed at 37 8C.
Measurements for this test series ran for 60 min.
2.1. Parameters of rotation thromboelastometry
ROTEMW defines various parameters to describe the
dynamics, the size and the firmness of clot during clot
formation and lysis (Fig. 1). The clotting time (CT) is the
period from the start of the analysis until the start of clot
formation, normally until the 2-mm amplitude is reached.
The clot formation time (CFT) is defined as the period until an
amplitude of 20 mm is reached. The angle alpha is given by
the angle between the centre line and a tangent to the curve
through the 2-mm amplitude point. The maximum amplitude
of the curve is defined as the maximum clot firmness (MCF).
The amplitude at different points of time is described by A5
till A30, whereby the number refers to the time since the
start of the test. The clot lysis index (CLI) at 30 and 60 min
(CLI30, CLI60) describes the ratio between the maximum clot
firmness and the amplitude 30 and 60 min after clotting time,
and gives information about the fibrinolysis. The maximum
lysis (ML) represents the maximum fibrinolysis detected
during the measurement.
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Fig. 1. Modified, with authorisation of Pentapharm GmbH, Munich, Germany.
CT (clotting time): time from the start of measurement until initiation of
clotting — initiation of clotting, thrombin formation, start of clot polymerisa-
tion. CFT (clot formation time): time from initiation of clotting until a clot
firmness of 20 mm is detected — fibrinpolymerisation, stabilisation of the clot
with thrombocytes and F XIII. MCF (maximum clot firmness): firmness of the
clot — increased stability of the clot by the polymerised fibrin, thrombocytes as
well as F XIII. Lysis: reduction of the clot firmness after MCF in relation to MCF —
stability of the clot. A maximum lysis (ML) <15% is considered normal, a ML
>15% within 1 h is indicative of exaggerated fibrinolysis (hyperfibrinolysis).The parameters measured in this study were: clotting
time, clot formation time, maximum clot firmness, angle
alpha, and amplitude after 5, 10, 15, 20, 25 and 30 min.
2.2. Test procedure
All ROTEMW devices used in this study were new and set up
by a representative of the local distributor. The tests were
performed using the automated pipette programmes accord-
ing to the instructions of the manufacturer. For each
measurement, a new pin was positioned on the axis of the
measurement channel and a new cup was put into the special
cup holder of the device. According to the pipetting
programme, 20 ml re-calcification reagent (200 mmol l1
calcium chloride solution) and 20 ml of the respective
activation reagent (FIBTEM: cytochalasin D, EXTEM: throm-
boplastin from rabbit brain and INTEM: partial thromboplas-
tin phospholipid made of rabbit brain (chloroform extract),
ellagic acid) were added into the pre-warmed cup. Then,
300 ml of citrated whole blood was added to the cup and,
after a semi-automated mixing step, the cup holder was
placed in the measuring position of the ROTEMW device. The
measurement started automatically when blood was added
to the cup and was stopped after 30 or 60 min according to
the protocol (EXTEM lot 41194401, INTEM lot 41166301,
FIBTEM lot 41147601, star-TEM lot 41166101).
2.3. Statistical analyses
A trial database within Excel (Microsoft Office 2003,
Microsoft Corporation Redmond, WA, USA) was used to store
study data (transferred from the ROTEMW devices). The
statistical analyses were performed using SPSSW (version 13,
SPSS Inc., Chicago, IL, USA). Continuous variables aresummarised as mean  SD and median with CI where
appropriate. Analysis of variance (ANOVA) for repeated
measures was used to analyse all parameters with post hoc
comparison and Bonferroni correction. For age and gender,
regression analyses were used. p Values of 0.05 or less are
considered significant.
3. Results
3.1. Baseline information
The 48 patients had a mean age of 50  22 years, ranging
from 17 to 87 years. For the 24 women, the mean age was
50  22 years, ranging from 17 to 85 years. For the 24 men,
the mean age was 50  22 years, ranging from 17 to 87 years.
The 10 volunteers were five men and five women; the overall
mean age was 37  14 years, ranging from 20 to 63 years.
3.2. Pre-analytic aspects’ stability over time
Over the time of 120 min, there was no significant
difference between any parameter in EXTEM, INTEM and
FIBTEM, indicating that ROTEMW measurements are stable
over 2 h at room temperature (Table 1).
3.3. Reproducibility and precision of ROTEMW devices
(intra- and inter-assay variability)
The reproducibility of results on two ROTEMW devices was
tested with 10 volunteers. Tests were performed twice with a
week’s interval in between; and an overall analysis was
performed between the two points of time (week 1 vs week 2)
and the two ROTEMW devices.
The reproducibility of maximum clot firmness in the 10
volunteers at the two points of time in the two ROTEMW
devices showed no significant difference between the two
points of time ( p > 0.200) and there was no influence by the
ROTEMW device ( p > 0.200) in the overall effect for EXTEM
(mean 63.0  5.5 mm, reference range 53—72 mm, mean
difference 0.1 mm, 95% CI 0.8 to 0.7 mm, maximum
difference 1.3%).
For the maximum clot firmness of FIBTEM (mean
11.9  3.7 mm, reference range 9—25 mm, mean difference
0.6 mm, 95% CI 0.2—1.0 mm, maximum difference 8.4%) and
INTEM (mean 61.6  4.3 mm, reference range 53—72 mm,
mean difference 1.7 mm, 95% CI 1.2—2.2 mm, maximum
difference 3.6%), a significant difference between devices
(FIBTEM p = 0.005, INTEM p < 0.001) but not for the points of
time (FIBTEM p > 0.200, INTEM p = 0.187) was found in the
overall analysis (Table 2, Fig. 2).
For EXTEM and FIBTEM, no significant difference between
devices or time points was found for clot formation time,
clotting time and angle alpha (Table 2). The clot formation
time ( p = 0.001, mean 74.5  20.1 s, reference range 35—
110 s, mean difference 7.1 s, 95% CI 10.4 to 3.7 s,
maximum difference 14.0%) and angle alpha ( p = 0.013,
mean 75.2  3.78, reference range 70—838, mean difference
1.28, 95% CI 0.3—2.18, maximum difference 2.8%) were
significantly different between devices in INTEM, but no
difference for the two points of time was found. For the two
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Table 2
MCF: maximum clot firmness, CFT: clot formation time, CT: clotting time and angle alpha changes between two ROTEMW devices and weeks 1 and 2, mean values and
standard deviations.
Test Week Device N MCF (mm) mean  SD CFT (s) mean  SD CT (s) mean  SD Angle alpha mean  SD
EXTEM 1 1 10 63.3  5.5 104.5  29.1 56.7  13.0 69.4  5.4
EXTEM 1 2 10 63.1  5.8 98.3  31.1 61.0  11.5 70.5  5.8
EXTEM 2 1 10 62.7  5.5 99.3  24.6 59.0  6.5 70.3  4.7
EXTEM 2 2 10 62.8  5.3 96.8  25.1 58.9  4.5 70.6  4.9
FIBTEM 1 1 10 11.4  4.0 * n.a. 57.9  10.4 n.a.
FIBTEM 1 2 10 12.2  4.2 * n.a. 57.3  7.3 n.a.
FIBTEM 2 1 10 11.7  3.2 * n.a. 54.6  7.2 n.a.
FIBTEM 2 2 10 12.1  3.2 * n.a. 54.1  5.2 n.a.
INTEM 1 1 10 60.9  4.8 * 77.2  22.5 * 155.7  17.7 ** 74.8  4.0 *
INTEM 1 2 10 62.9  4.3 * 68.8  21.1 * 157.0 12.0 ** 76.1  4.0 *
INTEM 2 1 10 60.5  4.0 * 78.8 18.6 * 164.1  12.6 ** 74.4  3.4 *
INTEM 2 2 10 61.9  4.0 * 73.1  18.0 * 160.3  18.7 ** 75.5  3.4 *
* p < 0.050 for ROTEMW devices.
** p < 0.050 for the weeks.
Table 1
Sample stability over the time, mean values and standard deviation.
CT (s) CFT (s)
T 0 T 30 min T 60 min T 90 min T 120 min T 0 T 30 min T 60 min T 90 min T 120 min
INTEM
Mean  SD 152.3  20.6 153. 6  16.9 154.7  20.0 156.5  21.4 156.0  20.1 64.7  15.1 62.9  15.4 64.1  16.1 61.3  15.5 61.6  14.8
EXTEM
Mean  SD 55.3  6.4 56.0  6.1 56.9  7.3 56.0  6.3 55.0  6.4 80.3  20.7 79.0  18.6 80.1  21.4 77.3  20.0 77.9  19.2
FIBTEM
Mean  SD 53.5  7.7 52.9  5.4 53.0  6.9 52.2  5.6 53.7  11.4 585.6  553.9 696.7  900.2 592.4  847.2 506.4  457.8 817.6  941.7
Alpha (8) MCF (mm)
T 0 T 30 min T 60 min T 90 min T 120 min T 0 T 30 min T 60 min T 90 min T 120 min
INTEM
Mean  SD 77.1  2.8 77.5  2.9 77.2  2.9 77.7  2.8 77.6  2.9 63.5  5.2 64.5  5.0 63.8  5.2 64.4  5.1 64.0  5.1
EXTEM
Mean  SD 73.9  4.1 74.0  3.8 74.0  4.2 74.4  3.9 74.2  3.8 66.7  5.5 66.3  5.0 66.2  5.3 66.3  5.1 66.5  5.3
FIBTEM
Mean  SD 69.9  6.9 71.2  5.3 70.8  6.3 70.1  6.1 71.8  5.0 16.1  5.9 16.3  5.8 16.6  6.0 16.7  6.2 16.1  5.6
MCF: maximum clot firmness, CFT; clot formation time, CT; clotting time.points of time, a significant difference was only found for the
clotting time (mean week one 156.4  14.9 s, mean week
two 162.2  15.7 s, reference range 100—240 s) in INTEM
( p = 0.046). For FIBTEM, the only analysis that is of
importance is maximum clot firmness; all other values are
not to be used in the interpretation of FIBTEM.
Reproducibility of results for maximum clot firmness was
97% in EXTEM, 95% in INTEM and 94% in FIBTEM. The
coefficient of variation was calculated in the first point of
time (week 1) on the same device. Coefficient of variation for
maximum clot firmness in EXTEM was <3%, INTEM <5% and
FIBTEM <6%. For clot formation time, the coefficient of
variation was <4% for EXTEM and <3%. INTEM. Coefficient of
variation for the angle alpha was <3% for EXTEM and <6% for
INTEM. Clotting time had a coefficient of variation of <15%
for EXTEM and INTEM.
3.4. Early prediction of maximum clot firmness
As tests for the 48 patients exceeded 60 min, we
calculated for each point of time the percentage of thefinal maximum clot firmness, showing that in an overall
analysis, after 10 min of running time, maximum clot
firmness in EXTEM, INTEM and FIBTEM reached at least 98%
of the final maximum clot firmness value.
3.5. Reference intervals
Reference intervals were calculated by means, according
to international guidelines, and adding one standard
deviation on either side. We also calculated reference
intervals by gender (Table 3). We were able to show that
reference intervals calculated in this study were closer
together than those set by the manufacturer. A gender-
specific influence is also to be seen.
3.6. Effect of age and gender
With advancing age, maximum clot firmness increased
significantly in all tests ( p < 0.001) by a mean of 0.1 mm per
year of age over 20 years. Angle alpha also increased
significantly for all tests with a mean of 0.078 per year of age
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Table 3
Reference values by themanufacture, reference values calculated in this study
and calculated by gender in this study.
Manufacturer Overall Male Female
EXTEM MCF (mm) 50—70 61—72 59—72 64—72
INTEM MCF (mm) 50—72 59—68 56—68 61—69
FIBTEM MCF (mm) 9—25 10—22 8—22 13—21
EXTEM CFT (s) 34—159 61—97 62—108 59—86
INTEM CFT (s) 30—110 49—77 51—86 47—68
FIBTEM CFT (s) n.a. n.a. n.a. n.a.
EXTEM CT (s) 38—79 48—63 50—65 46—62
INTEM CT (s) 100—240 133—177 131—182 134—171
FIBTEM CT (s) 43—75 48—58 51—59 46—56
EXTEM angle alpha (8) 63—83 70—78 68—78 73—78
INTEM angle alpha (8) 70—83 75—80 73—80 76—81
FIBTEM angle alpha (8) n.a. n.a. n.a. n.a.
MCF: maximum clot firmness, CFT: clot formation time, CT: clotting time.
Fig. 2. Boxplot of MCF: maximum clot firmness for all tests, representing
median by device 1 and 2 and point of time 1 and 2, *p < 0.050 for differences
between ROTEMW devices.over 20 years in EXTEM ( p = 0.009), 0.148 in FIBTEM
( p = 0.007) and 0.048 in INTEM ( p = 0.019). Clot formation
time decreased significantly in EXTEM ( p = 0.008) and INTEM
( p = 0.014), with a mean of 0.4 s per year of age over 20Table 4
Sex related differences in the main parameters of ROTEMW, mean values and stand
Age (years) CT (s)
INTEM
Females (n = 24) 50.8  21.9 152.5  18.1
Males (n = 24) 52.0  22.1 156.8  25.5
EXTEM
Females (n = 24) 50.8  21.9 53.9  7.8
Males (n = 24) 52.0  22.1 57.7  7.3
FIBTEM
Females (n = 24) 50.8  21.9 51.1  5.0
Males (n = 24) 52.0  22.1 55.0  4.2
MCF: maximum clot firmness, CFT: clot formation time, CT: clotting time.
* p < 0.050 comparison male versus female.years in EXTEM and 0.2 s per year of age over 20 years in
INTEM. The age had no influence on clotting time in all tests.
Maximum clot firmness ( p < 0.001 for EXTEM and INTEM)
and angle alpha ( p = 0.009 in EXTEM, p = 0.019 in INTEM)
were significantly higher and clot formation time lower
( p = 0.008 in EXTEM, p = 0.014 in INTEM) in EXTEM and INTEM
in women than in men, indicating a somewhat greater
coagulability in women. Similar changes in FIBTEM (towards
hypercoagulability) did not reach statistical significance.
Clotting time was similar in all age groups and in both sexes
(Table 4).
4. Discussion
Our analysis of pre-analytic aspects showed that ROTEMW
tests yield stable results from citrated blood that was re-
calcified during the first 120 min. This is of high practical
relevance since the exact delay from blood drawing to testing
would be difficult to standardise, particularly in major
trauma. This is in contrast to the thromboelastography,
where a previous report showed that parameters are
unstable in the first 30 min after blood withdrawal [10].
Evaluation of the second aim (reproducibility: inter-assay,
same device) showed a good reproducibility of results on the
same ROTEMW device as well as over a time period of 120 min.
Statistically significant differences on different ROTEMW
devices occurred for the maximum clot firmness of FIBTEM
and INTEM as well as the clot formation time and alpha angle
of INTEM as mentioned above. For the interpretation of
INTEM, these results are statistically significant but not of any
clinical relevance because the values are largely within the
reference values and would not be implemented in a
treatment. Reference intervals calculated for our study
and for gender were found to be within a narrower interval
than those provided by the manufacturer. According to the
manufacturer, the company’s reference values are for
orientation purposes and should be validated individually,
as they may vary from lab to lab, depending on blood
sampling technology and other pre-analytical factors.
Evaluation of the third aim (precision: inter-device)
demonstrated reproducibility of ROTEMW measurements
over time and when the blood sample is analysed on the
same ROTEMW device sequentially. In addition, citrated blood
samples analysed after 0—120 min yield similar results in allard deviations.
CFT (s) Alpha angle (8) MCF (mm)
57.7  10.5 * 78.4  2.1 * 64.8  3.8 *
68.1  17.5 * 76.5  3.2 * 62.2  6.1 *
72.6  13.3 * 75.3  2.7 * 68.1  4.2 *
85.2  23.2 * 72.9  4.6 * 65.3  6.4 *
n.d. 71.0  5.6 17.3  4.1
n.d. 70.4  6.5 15.0  7.2
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analysed on different ROTEMW devices simultaneously,
statistically significant differences ( p < 0.050) were
detected in the overall comparison for the maximum clot
firmness in FIBTEM (maximum difference 8.4%) and in INTEM
(maximum difference 3.6%) as well as for clot formation time
(maximum difference 14%) and angle alpha (maximum
difference 2.8%) in INTEM. In clinical use, when using
algorithms, a difference in maximum clot firmness of 1—
2 mm in FIBTEM may result in a premature or delayed
treatment of the patient. Therefore, when working with
exact algorithms, the blood of one individual patient should
be measured on one single ROTEMW device.
Compared with the results of Lang et al. [13], we have
found a somewhat lower variability for the maximum clot
firmness in the FIBTEM test (coefficient of variability for
maximum clot firmness <6%). This may be due to the fact
that, in our study, only three persons performed all ROTEMW
tests, which is impossible when pooling data from different
centres. Performing ROTEMW tests by persons familiar
with the ROTEMW technology thus appear to reduce the
variability.
A progressive change of the ROTEMW parameters towards
hypercoagulability with advancing age as observed in this
study has also been described by Ng [14] for thromboelasto-
graphy (TEGW Haemoscope Corporation, Skokie, IL, USA), and
is in keeping with previous reports describing hypercoagul-
ability in elderly people [14,15]. Since the ROTEMW
parameters measured in the current study were still within
the reference ranges provided by the manufacturer, an age-
specific adaptation of the reference ranges may not be
required for ROTEMW. Nevertheless, the trend of increased
clot firmness at advanced age should be kept in mind in the
clinical interpretation of ROTEMW results.
We found differences between men and women in
ROTEMW parameters, which indicate a faster development
of the clot and greater clot strength in women as compared
with men (Table 4). Unfortunately, no measurements of
fibrinogen according to Clauss were performed in this study.
Nevertheless, this may represent a factor predisposing
women to thrombotic complications [16].
A limitation of this study is that we did not take into
account the effective temperature in patients since it is
known to impair results and interpretation of ROTEMW [17].
We think that this point is of limited importance since the
ROTEMW devices work at a temperature of 37 8C and the
300 ml of blood drawn are at this same temperature and the
patients were not hypothermic at the moment the blood was
drawn.
ROTEMW results cannot give exact recommendations on
the amount of blood products or coagulation factors to be
administered. However, ROTEMW can guide the clinician as to
which type of treatment may be most helpful to treat
coagulopathy during surgery or in trauma. In 2007, Rugeri
et al. demonstrated in trauma patients that ROTEMW can
rapidly detect trauma-related coagulopathy and might be
helpful in guiding treatment [18]. Theusinger et al. [19]
published a ROTEMW-based transfusion algorithm to guide
individual goal-directed transfusions. A retrospective analy-
sis by Anderson et al. [20] in 990 patients showed that the use
of ROTEMW significantly decreases the use of red blood cellsand other blood products after cardiac surgery. This is
particularly important given the fact that red blood cell
transfusion in cardiac surgery is consistently associated with
significant morbidity and increased mortality [21—24]. Last
but not least, Spalding et al. have demonstrated that a
ROTEMW-based coagulation algorithm decreased total trans-
fusion costs in cardiac surgery [25].
5. Conclusion
ROTEMW measurements of EXTEM, INTEM and FIBTEM are
reproducible and stable over time, regardless of delay from
blood withdrawal to analysis (range 0—120 min after blood
withdrawal). There is a high reproducibility with the
coefficient of variation <6% in all assays. Coefficient of
variation for maximum clot firmness in EXTEM was <3%,
INTEM <5% and FIBTEM <6%; they are small but statistically
significant. With age, there is a tendency of hypercoagul-
ability and also with sex: women seem to coagulate better
than men but within range. To avoid problems in treating
coagulopathies when working with an algorithm or to
interpret the evolution of ROTEMW parameters over time,
ROTEMW tests should preferably be performed on the same
ROTEMW device, because in our study one ROTEMW device
yielded slightly but statistically significantly different results
for maximum clot firmness and clot formation time.
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